AstraZeneca badly needs new drugs on the market as several former blockbusters have been hit by generic competition – and finally its high potassium treatment Lokelma has been approved by U
First quarter results from AstraZeneca have disappointed investors, sending shares down on the London Stock Exchange, as the UK firm continued to feel the effects of patent losses on key dr
AstraZeneca had placed its immunotherapy Imfinzi (durvalumab) at the centre of its efforts to rebuild its sales – but after a shock failure last year in first line lung cancer, the drug has
